ARS Pharmaceuticals, Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
ARS Pharmaceuticals, Inc. (SPRY) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $300.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2025-11-10
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $300.00K.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $310.00K.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $310.00K 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |